326 related articles for article (PubMed ID: 7796391)
1. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
Wang Y; Becker D
Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
[TBL] [Abstract][Full Text] [Related]
3. Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells.
Zhang H; Rosdahl I
Int J Oncol; 2004 Feb; 24(2):331-5. PubMed ID: 14719109
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Geradts J; Kratzke RA; Niehans GA; Lincoln CE
Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382
[TBL] [Abstract][Full Text] [Related]
5. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
Glendening JM; Flores JF; Walker GJ; Stone S; Albino AP; Fountain JW
Cancer Res; 1995 Dec; 55(23):5531-5. PubMed ID: 7585628
[TBL] [Abstract][Full Text] [Related]
6. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
[TBL] [Abstract][Full Text] [Related]
7. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
[TBL] [Abstract][Full Text] [Related]
8. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis.
Luca M; Xie S; Gutman M; Huang S; Bar-Eli M
Oncogene; 1995 Oct; 11(7):1399-402. PubMed ID: 7478563
[TBL] [Abstract][Full Text] [Related]
9. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
Kamb A; Shattuck-Eidens D; Eeles R; Liu Q; Gruis NA; Ding W; Hussey C; Tran T; Miki Y; Weaver-Feldhaus J
Nat Genet; 1994 Sep; 8(1):23-6. PubMed ID: 7987388
[TBL] [Abstract][Full Text] [Related]
12. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.
Straume O; Sviland L; Akslen LA
Clin Cancer Res; 2000 May; 6(5):1845-53. PubMed ID: 10815907
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
Elisei R; Shiohara M; Koeffler HP; Fagin JA
Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
[TBL] [Abstract][Full Text] [Related]
14. The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas.
Polsky D; Young AZ; Busam KJ; Alani RM
Cancer Res; 2001 Aug; 61(16):6008-11. PubMed ID: 11507043
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product/p16.
Wick ST; Dubay MM; Imanil I; Brizuela L
Oncogene; 1995 Nov; 11(10):2013-9. PubMed ID: 7478520
[TBL] [Abstract][Full Text] [Related]
16. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
Keller-Melchior R; Schmidt R; Piepkorn M
J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
[TBL] [Abstract][Full Text] [Related]
17. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
18. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
19. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
Oncogene; 1995 Mar; 10(6):1061-7. PubMed ID: 7700630
[TBL] [Abstract][Full Text] [Related]
20. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.
Flores JF; Walker GJ; Glendening JM; Haluska FG; Castresana JS; Rubio MP; Pastorfide GC; Boyer LA; Kao WH; Bulyk ML; Barnhill RL; Hayward NK; Housman DE; Fountain JW
Cancer Res; 1996 Nov; 56(21):5023-32. PubMed ID: 8895759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
